Eton Pharmaceuticals Inc (NASDAQ:ETON) – Stock analysts at B. Riley upped their Q3 2020 earnings per share estimates for Eton Pharmaceuticals in a research note issued on Tuesday, October 22nd. B. Riley analyst A. D’silva now expects that the company will post earnings of ($0.21) per share for the quarter, up from their prior estimate of ($0.22). B. Riley currently has a “Buy” rating and a $13.50 target price on the stock. B. Riley also issued estimates for Eton Pharmaceuticals’ Q4 2020 earnings at ($0.19) EPS, FY2020 earnings at ($0.79) EPS and FY2021 earnings at ($0.44) EPS.
Several other research firms also recently commented on ETON. ValuEngine upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target (up previously from $18.00) on shares of Eton Pharmaceuticals in a report on Wednesday. Finally, Lake Street Capital started coverage on shares of Eton Pharmaceuticals in a research note on Monday, August 5th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Eton Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $13.67.
Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.12.
In related news, CEO Sean Brynjelsen acquired 5,000 shares of the stock in a transaction dated Tuesday, August 13th. The stock was acquired at an average cost of $6.15 per share, for a total transaction of $30,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 13.46% of the company’s stock.
Several large investors have recently bought and sold shares of ETON. BlackRock Inc. lifted its stake in shares of Eton Pharmaceuticals by 181.2% during the second quarter. BlackRock Inc. now owns 26,092 shares of the company’s stock worth $206,000 after buying an additional 16,813 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Eton Pharmaceuticals by 122.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,139 shares of the company’s stock worth $25,000 after buying an additional 1,728 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Eton Pharmaceuticals by 6.7% during the second quarter. Vanguard Group Inc. now owns 28,762 shares of the company’s stock worth $227,000 after buying an additional 1,800 shares during the period. Institutional investors and hedge funds own 9.95% of the company’s stock.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
Featured Article: What does RSI mean?
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.